Before a technology transfer office (TTO) ever proposes an upfront fee or a royalty percentage, someone in the office has already answered a quieter set of questions: how far along is this technology, how big is the market for it, who else is working on something similar, and how strong is the underlying IP position. Those questions — not the pricing math itself — are what this guide covers. For the formal three-approach valuation framework (income, market, and cost), see CASRAI’s Patent Valuation Methods guide. For the mechanics of how a license is actually priced once negotiation starts — upfront fees, running royalties, milestone payments, and equity — and typical rate ranges, see Patent Licensing: Exclusive Terms, Royalties, and Startup vs. Established Deals. For royalty-rate math specifically, including the 25% Rule and comparables method, see Royalty Rate Setting. This page sits upstream of all three: it walks through the assessment a licensing officer actually performs, and shows how the answers to that assessment shape which pricing structure ends up on the term sheet.
The Two Decisions Behind Every License
The Licensing Executives Society (LES) organizes its Certified Licensing Professional (CLP) credential around a recognized four-phase practical sequence: opportunity assessment and valuation, agreement drafting, negotiation, and agreement management. Evaluation and pricing both live inside that first phase, but they answer different questions. Evaluation asks: what do we actually have, and how commercially ready is it? Pricing asks: given that assessment, what should a licensee pay, and in what form? A TTO that skips straight to a royalty percentage without doing the evaluation work first is negotiating from a weak position — it has no internal basis for judging whether a licensee’s offer is reasonable, and no rationale to fall back on when a term is contested.
Assessing Development Stage: Where Is the Technology on the TRL Scale?
Most TTOs describe how far a technology has progressed using the Technology Readiness Level (TRL) scale, a nine-level framework originally developed at NASA in the 1970s and later adopted by the Department of Defense, the Department of Energy, the European Commission’s Horizon Europe programme, and NSF programs including its Regional Innovation Engines. TRL 1–3 covers basic principles through proof-of-concept; TRL 4–6 covers component and prototype validation and demonstration in a relevant or operational environment; TRL 7–9 covers a system proven through actual operational use. Most university inventions disclosed to a TTO sit in the TRL 1–4 range — far earlier than what a corporate licensee’s own R&D pipeline typically starts from. That gap matters directly for pricing: a lower TRL means more of the commercialization risk and remaining development cost still sits with the licensee, which is exactly the leverage point that shapes how a license’s consideration gets structured (see below). See CASRAI’s Technology Readiness Level (TRL) entry for the full nine-level definition table.
Assessing Market Size and Competitive Landscape
Development stage answers "how far along is it"; market assessment answers "how big is the opportunity, and to whom." A licensing officer typically works through three related questions. First, how many plausible licensees exist for this technology — is it a narrow application that fits one company’s product line, or a broadly useful platform, reagent, or research tool that many labs or companies could use? That distinction directly informs the exclusivity decision: a single-product, high-investment technology usually needs an exclusive license to give one licensee the confidence to fund years of further development, while a broadly applicable platform technology often generates more total value licensed non-exclusively to many users than locked up with one (see CASRAI’s Exclusive License vs. Non-Exclusive License comparison). Second, what have comparable technologies actually licensed for — this is the same comparable-transaction research that underlies the market approach in formal patent valuation (see Patent Valuation Methods) and the comparables method used in royalty-rate setting (see Royalty Rate Setting). Third, what does the competitive and patent landscape look like — are there blocking patents, close substitutes, or a crowded field that would erode a licensee’s exclusivity value even with a valid license in hand? A preliminary landscape review at this stage is not the same as a formal freedom-to-operate (FTO) opinion; it’s a lighter-weight scan to gauge whitespace before investing further TTO time and patent-prosecution budget.
Assessing IP Strength, Freedom to Operate, and Remaining Risk
The technology’s commercial promise only matters if the IP position actually protects it. Evaluation here typically covers claims scope (how broad or narrow the patent claims are relative to the commercial embodiment a licensee would actually sell), prosecution status and cost (issued vs. pending, in how many jurisdictions, and what maintenance-fee and future prosecution spend the TTO is committing to), and what technical or regulatory work still separates the invention from a marketable product. On freedom to operate specifically: by convention, most university TTOs do not warrant FTO as part of a license — a licensee’s actual FTO exposure depends on the specific product it eventually builds, which the university doesn’t control, so the license typically discloses what the TTO knows rather than promising a clean landscape. See CASRAI’s Freedom to Operate (FTO) Analysis entry. A prospective licensee will independently probe most of these same evaluation categories — IP ownership and chain of title, Bayh-Dole compliance history, FTO and prior art, and commercialization readiness — through its own formal information request once it’s seriously interested; see CASRAI’s Due Diligence Questionnaire (DDQ) in Technology Licensing guide for what that request typically asks and how a TTO prepares to answer it credibly. This guide covers the TTO’s own internal evaluation, ahead of and independent from that licensee-driven diligence process; the earlier patentability screening a disclosure goes through before any of this is covered in CASRAI’s Patentability Assessment guide.
From Assessment to Deal Structure
Each evaluation factor above has a direct, recognizable effect on how a license ends up priced. A technology at low TRL, in an unproven or narrow market, with no directly comparable licenses to point to, is difficult to price with a meaningful upfront fee or an aggressive royalty — the licensee is still taking on most of the risk, so consideration tends to weight toward milestone payments (tied to development or regulatory checkpoints the licensee has to clear anyway) and, for a startup licensee with no product revenue yet, equity in place of cash. A technology at higher TRL, in a market with real comparable transactions and multiple interested parties, supports a larger upfront fee and a royalty benchmarked against those comparables. University consideration for a license is rarely a single number; it is typically some combination of an upfront fee, a running royalty on net sales, milestone payments, and, for startup licensees, equity — CASRAI’s Patent Licensing guide walks through each of these four components in detail, including typical (though non-fixed) royalty-rate ranges, and License Agreement Structure covers how they get drafted into the agreement itself. For the specific question of cash royalty versus equity consideration in a startup deal, see CASRAI’s Royalty vs. Equity Licensing Compensation comparison; for the related question of whether to sign a license outright or an option first while a startup still needs to raise funding, see Option Agreement vs. License Agreement.
Where the 25% Rule Fits, and Where It Doesn’t
One reference point that comes up repeatedly in these conversations is the "25% Rule" — a rule of thumb, originated by licensing economist Robert Goldscheider from a late-1950s study of commercial licenses, that allocates roughly a quarter of a licensee’s expected profit attributable to the patented technology to the licensor as royalty. It is a useful, fast mental anchor, but it is not a substitute for the market-comparables and income-projection work described above — and it has real legal limits: the rule was held inadmissible as an expert-testimony damages methodology by the Federal Circuit in Uniloc USA, Inc. v. Microsoft Corp. (2011), which vacated a jury damages award built on it, on the grounds that it doesn’t apportion value between the patented feature and the rest of the product. Litigation-context royalty analysis instead uses the 15-factor Georgia-Pacific framework, which is also widely used outside litigation as a structuring checklist. Treat the 25% Rule as one directional reference point among several — alongside comparable licenses, an income-approach projection, and Georgia-Pacific-style factors — not as a formula a TTO should apply on its own. CASRAI’s Royalty Rate Setting guide covers this history and the comparables method in full.
A Practical Evaluation Checklist
Licensing officers working through a new opportunity typically move through some version of the following, roughly in this order:
- IP ownership and chain of title, including inventor assignments and, for federally funded work, Bayh-Dole election-of-title and reporting status.
- Patent claims scope, prosecution status (pending vs. issued, jurisdictions), and the maintenance and future prosecution budget the technology is committing the institution to.
- Technology Readiness Level and what technical or regulatory work remains before the invention is a marketable product.
- Market size — how many plausible licensees exist, and whether the technology is a single-product opportunity or a broadly useful platform.
- Competitive and patent landscape, including a preliminary freedom-to-operate scan.
- Licensee profile — an established company with product revenue can typically support a larger upfront fee and a straightforward royalty; an early-stage startup usually cannot, which is why milestone and equity structures show up disproportionately in spinout licenses (see CASRAI’s guides on university spinout resources and spinout funding options).
- Mission-related licensing considerations — many U.S. research universities follow some version of AUTM’s 2007 statement "In the Public Interest: Nine Points to Consider in Licensing University Technology," which asks TTOs to weigh factors like public health access and responsible use alongside pure revenue maximization when structuring a license.
Frequently Asked Questions
Is there a standard royalty rate for university licenses?
No. Reported ranges run roughly 1%–10% of net sales across industry and TTO sources, with rates in the low-to-mid single digits more typical for early-stage academic technology, but the actual rate in any given deal depends on development stage, market size, and remaining licensee investment — see Royalty Rate Setting.
Does a university TTO guarantee freedom to operate?
Generally no. Most university licenses disclaim any freedom-to-operate warranty, because FTO exposure depends on the specific product the licensee ultimately builds, which the university doesn’t control. The TTO discloses what it knows; the licensee is expected to run its own independent FTO analysis.
What’s the difference between valuing a patent and setting a royalty rate?
Valuation answers "what is this asset worth" using the income, market, or cost approach (see Patent Valuation Methods); royalty-rate setting answers "given that we’re licensing it, what percentage or fee is fair" within an already-agreed license. A valuation exercise often feeds directly into the royalty conversation, but the two are distinct questions.
Why do universities take equity instead of royalties in some licenses?
A pre-revenue startup licensee has no net sales to base a royalty on, so many universities take an equity stake — in place of, or alongside, a reduced upfront fee — to align the institution’s return with the startup’s eventual success. See Royalty vs. Equity Licensing Compensation.
For the broader lifecycle this evaluation-and-pricing stage fits into, see CASRAI’s Technology Transfer Process guide, and for an overview of the full cluster, see the Technology Transfer & Innovation pillar page.
